{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T11:58:55Z","timestamp":1756382335826},"reference-count":35,"publisher":"Royal College of Psychiatrists","issue":"6","license":[{"start":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T00:00:00Z","timestamp":1517184000000},"content-version":"unspecified","delay-in-days":11747,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[1985,12]]},"abstract":"<jats:p>Patients with chronic schizophrenia were treated with either propranolol (640 mg daily) or thioridazine (400 mg daily). In a double-blind study lasting five weeks, propranolol was superior to thioridazine on both psychiatrists' and nurses' ratings. Significant improvements were noted with propranolol in both positive (Type I) and negative (Type II) symptoms.<\/jats:p>","DOI":"10.1192\/bjp.147.6.623","type":"journal-article","created":{"date-parts":[[2008,8,12]],"date-time":"2008-08-12T23:20:52Z","timestamp":1218583252000},"page":"623-630","source":"Crossref","is-referenced-by-count":24,"title":["The Effect of Propranolol and Thioridazine on Positive and Negative Symptoms of Schizophrenia"],"prefix":"10.1192","volume":"147","author":[{"given":"D.","family":"Eccleston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. F.","family":"Fairbairn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Hassanyeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. A.","family":"McClelland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. A.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"170","published-online":{"date-parts":[[2018,1,29]]},"reference":[{"key":"S0007125000208799_ref16","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.137.5.458"},{"key":"S0007125000208799_ref23","doi-asserted-by":"publisher","DOI":"10.1038\/259488a0"},{"key":"S0007125000208799_ref13","first-page":"409","article-title":"Reine Defektsyndrome und Basisstadien endogener Psychosen","volume":"34","author":"Huber","year":"1966","journal-title":"Fortschr. Neurol. Psychiat."},{"key":"S0007125000208799_ref11","doi-asserted-by":"publisher","DOI":"10.2466\/pr0.1966.19.1.180"},{"key":"S0007125000208799_ref8","first-page":"1","article-title":"Antagonism between lysergic acid diethylamide and 5-hydroxytryptamine","volume":"121","author":"Gaddum","year":"1953","journal-title":"Journal of Physiology"},{"key":"S0007125000208799_ref6","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1965.01730060070010"},{"key":"S0007125000208799_ref18","doi-asserted-by":"publisher","DOI":"10.1126\/science.7350667"},{"key":"S0007125000208799_ref21","doi-asserted-by":"publisher","DOI":"10.1038\/267289a0"},{"key":"S0007125000208799_ref1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.138.3.268"},{"key":"S0007125000208799_ref7","first-page":"493","article-title":"Anti-psychotic activity and mode of action of propranolol vs neuroleptic drugs","volume":"14","author":"Elizure","year":"1978","journal-title":"Israel Journal of Medical Science"},{"key":"S0007125000208799_ref25","doi-asserted-by":"publisher","DOI":"10.2466\/pr0.1962.10.3.799"},{"key":"S0007125000208799_ref20","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.137.2.126"},{"key":"S0007125000208799_ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)90193-9"},{"key":"S0007125000208799_ref17","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.37.8.941"},{"key":"S0007125000208799_ref9","doi-asserted-by":"publisher","DOI":"10.1038\/262594a0"},{"key":"S0007125000208799_ref19","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.113.502.950"},{"key":"S0007125000208799_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(75)90454-3"},{"key":"S0007125000208799_ref2","volume-title":"The Chronic Schizophrenias","author":"Astrup","year":"1979"},{"key":"S0007125000208799_ref10","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1980.01780190083010"},{"key":"S0007125000208799_ref22","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.139.2.118"},{"key":"S0007125000208799_ref12","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(78)90030-1"},{"key":"S0007125000208799_ref5","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1192\/S0007125000071919","article-title":"Positive and negative schizophrenic symptoms and the role of dopamine","volume":"137","author":"Crow","year":"1980","journal-title":"British Journal of Psychiatry"},{"key":"S0007125000208799_ref28","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.143.2.151"},{"key":"S0007125000208799_ref31","volume-title":"Research Diagnostic Criteria (RDC) for a Selected Group of Functional Disorders","author":"Spitzer","year":"1977"},{"key":"S0007125000208799_ref29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)90939-4"},{"key":"S0007125000208799_ref30","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.5.470"},{"key":"S0007125000208799_ref24","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.113.501.813"},{"key":"S0007125000208799_ref32","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291700048480"},{"key":"S0007125000208799_ref33","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.129.2.125"},{"key":"S0007125000208799_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(70)90447-2"},{"key":"S0007125000208799_ref35","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.4.5945.633"},{"key":"S0007125000208799_ref15","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1983.01790030034004"},{"key":"S0007125000208799_ref26","article-title":"Propranolol in schizophrenia. Comparison of propranolol, chlorpromazine and placebo","volume":"139","author":"Peet","year":"1981","journal-title":"British Journal of Psychiatry"},{"key":"S0007125000208799_ref34","article-title":"Propranolol as an adjunct to the treatment of schizophrenia","volume":"ii","author":"Yorkston","year":"1977","journal-title":"Lancet"},{"key":"S0007125000208799_ref27","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.115.523.679"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000208799","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T16:30:39Z","timestamp":1588869039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000208799\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,12]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1985,12]]}},"alternative-id":["S0007125000208799"],"URL":"https:\/\/doi.org\/10.1192\/bjp.147.6.623","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[1985,12]]}}}